Natalizumab is used for the research of relapsing-remitting multiple sclerosis and Crohn's disease; it inhibits lymphocyte migration into the central nervous system, thereby preventing acute demyelinating relapses; it reduces inflammation and prevents lesion formation by blocking the interaction between α4β1-integrin and vascular cell adhesion molecule-1 (VCAM-1); it may also inhibit ongoing central nervous system (CNS) inflammation mediated by leukocytes already present in the CNS by disrupting interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin.